Latest News and Press Releases

NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that DBM Global Inc. (“DBMG”), a family of companies providing fully integrated...

NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that DBM Global Inc. (“DBMG”), has entered into an amended and restated credit...

- Infrastructure: DBM Global first quarter revenue of $264.9 million -- Life Sciences: MediBeacon® Transdermal GFR (“TGFR”) System Received FDA Approval to Assess Kidney Function -- Spectrum: Expects...

NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the first quarter 2025 on...

- Infrastructure: DBM Global fourth quarter revenue of $225.7 million -- Life Sciences: MediBeacon® Transdermal GFR (“TGFR”) system received FDA approval to assess kidney function -- Spectrum:...

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the fourth quarter and full year...

Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function.The Clinical Kidney Journal in February...

Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal functionThe transdermal GFR (tGFR) methodology has...

NEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) -- R2 Technologies, Inc., the world leader in CryoAesthetics® with its cutting-edge Glacial Skin systems (“R2”), a portfolio company of INNOVATE Corp. (NYSE:...

- Infrastructure: DBM Global third quarter revenue of $232.8 million -- Life Sciences: R2 reports record worldwide system unit sales growth in the third quarter -- Spectrum: Broadcasting's delivered...